Isomorphic Labs

Isomorphic Labs, a London-based AI drug discovery firm spun out of Google DeepMind, is reportedly in early-stage discussions to secure fresh funding at a valuation of up to $50 billion. This potential raise follows a major $2.1 billion Series B round completed in May, alongside a $600 million raise in March 2025.

Summary of transaction details:

• Value: $2.1 billion (Series B) / Target Valuation up to $50 billion
• Sector: Healthcare & Biotech
• Advisor: None
• Key Entities: Isomorphic Labs, Alphabet, Thrive Capital, UK Sovereign AI Fund
• Location: London, United Kingdom

Note: Led by Nobel laureate Sir Demis Hassabis, Isomorphic Labs leverages AlphaFold technology to predict how molecules interact with biological targets. While the firm has attracted massive investor interest, its AI-discovered treatments have yet to enter human clinical trials, which are currently slated to begin by the end of 2026.